Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Innovent Biologics (HK:1801)
HKEX:1801
Holding HK:1801?
Track your performance easily
See the Price Targets and Ratings of:
1801 Analyst Ratings
Strong Buy
5 Buy
0 Hold
0 Sell
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months
1801 Stock 12 Month Forecast
Average Price Target
HK$53.62
▲(38.02% Upside)
| Highest Price TargetHK$58.07 | Average Price TargetHK$53.62 | Lowest Price TargetHK$46.98 |
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.
Detailed List of Analyst Forecasts
Ranks
Any
Analyst Rating
Any
Upside/ Downside
Any
Action
Any
CMB International Securities
Reiterated
11/05/24
J.P. Morgan
Reiterated
10/28/24
Nomura
Reiterated
08/29/24
Bernstein
Reiterated
08/28/24
Morgan Stanley
Assigned
06/25/24
CLSA
HK$64.5→HK$57.5
Buy
48.01%
Upside
Reiterated
03/21/24
Innovent Biologics Inc. (1801:HK) (IVBXF) PT Lowered to HK$57.50 at CLSACLSA analyst Matthew Yan lowered the price target on Innovent Biologics Inc. (1801:HK) (OTC: IVBXF) to HK$57.50 (from HK$64.50) while maintaining a Buy (1) rating.
Macquarie
HK$34→HK$37
Hold
-4.76%
Downside
Reiterated
03/13/24
Innovent Biologics Inc. (1801:HK) (IVBXF) PT Raised to HK$37 at MacquarieMacquarie analyst Tony Ren raised the price target on Innovent Biologics Inc. (1801:HK) (OTC: IVBXF) to HK$37.00 (from HK$34.00) while maintaining a Neutral rating.
Citi
HK$50→HK$62
Buy
59.59%
Upside
Reiterated
11/10/23
Innovent Biologics Inc. (1801:HK) (IVBXF) PT Raised to HK$62 at CitiCiti analyst John Yung raised the price target on Innovent Biologics Inc. (1801:HK) (OTC: IVBXF) to HK$62.00 (from HK$50.00) while maintaining a Buy rating.
―
Jefferies
―
Buy
―
Reiterated
10/25/24
Unknown Analyst
Not Ranked
HSBC
HK$55
Buy
41.57%
Upside
Reiterated
03/26/24
Innovent Biologics Inc. (1801:HK) (IVBXF) PT Raised to HK$55 at HSBC, 'promising ADC and bispecific antibody readouts could be catalysts'The analyst commented: "2023 revenue beat our expectation but earnings missed. Launch of GLP-1/GCGR, and promising ADC and bispecific antibody readouts could be catalysts. Maintain Buy rating, raise TP to HKD55.00 from HKD53.00."
Best Analysts Covering Innovent Biologics
Which Analyst Should I Follow If I Want to Buy HK:1801 and Sell After:
1 Month
xxx
Success Rate
4/7 ratings generated profit
Average Return
+8.33%
reiterated a xxx
rating 13 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 1 Month would result in 57.14% of your transactions generating a profit, with an average return of +8.33% per trade.
3 Months
xxx
Success Rate
4/6 ratings generated profit
Average Return
+2.37%
reiterated a xxx
rating 5 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 3 Months would result in 66.67% of your transactions generating a profit, with an average return of +2.37% per trade.
1 Year
2 Years
xxx
Success Rate
6/11 ratings generated profit
Average Return
+10.12%
reiterated a xxx
rating 2 months ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 2 Years would result in 54.55% of your transactions generating a profit, with an average return of +10.12% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.
1801 Analyst Recommendation Trends
Rating
Jun 24
Jul 24
Aug 24
Oct 24
Nov 24
Strong Buy
11
6
9
7
7
Buy
0
0
0
0
0
Hold
1
0
1
1
1
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
12
6
10
8
8
Each month's total comprises the sum of three months' worth of ratings.
1801 Financial Forecast
1801 Stock Forecast FAQ
What is HK:1801’s average 12-month price target, according to analysts?
Based on analyst ratings, Innovent Biologics’s 12-month average price target is HK$53.62.
What is HK:1801’s upside potential, based on the analysts’ average price target?
Innovent Biologics has 38.02% upside potential, based on the analysts’ average price target.
Can I see which stocks the top-ranking analysts are rating?
Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
How can I follow the stock ratings of top Wall Street analysts?
Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
Is Innovent Biologics a Buy, Sell or Hold?
Innovent Biologics has a consensus rating of Strong Buy, which is based on 5 buy ratings, 0 hold ratings and 0 sell ratings.
What is Innovent Biologics’s share price target?
The average share price target for Innovent Biologics is HK$53.62. This is based on 5 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst share price target is HK$58.07 ,and the lowest forecast is HK$46.98. The average share price target represents 38.02% Increase from the current price of HK$38.85.
The highest analyst share price target is HK$58.07 ,and the lowest forecast is HK$46.98. The average share price target represents 38.02% Increase from the current price of HK$38.85.
What do analysts say about Innovent Biologics?
Innovent Biologics’s analyst rating consensus is a Strong Buy. This is based on the ratings of 5 Wall Streets Analysts.
How can I buy shares of Innovent Biologics?
To buy shares of HK:1801, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.